Proactive Investors - Run By Investors For Investors

Sareum makes strong progress on cancer and autoimmune disease therapies

Sareum said it would continue talks with potential licence partners for its therapies under development
Sareum makes strong progress on cancer and autoimmune disease therapies
Sareum specialises in small molecule drug development

Sareum Holdings Plc (LON:SAR) swung to a full-year loss but said it had made strong progress with potential therapies for certain cancers and autoimmune diseases during the year.

The company, which specialises in small molecule drug development, on Monday reported an operating loss of £1.7mln in the year to the end of June compared to the profit of £0.35mln it made a year ago.

READ: Sareum selects potential anti-cancer molecule for further development

Sareum it was pleased with the progress Sierra Oncology was making with SRA737 (to potentially treat tumours identified to have genetic aberration) in expanding and adapting the clinical development programme based on cutting-edge science and emerging data. It expects the preliminary clinical data to be available in the first half of 2019, and the start of a third clinical trial of SRA737 in combination with niraparib to start before the end of 2018.

The AIM-listed company said that potential of TYK2/JAK1 inhibitors - potential therapies for certain cancers - as a treatment modality was gaining increasing clinical and commercial validation and that it believes it has strong candidates with optimised profiles in these areas.

"The advancement of these candidates through preclinical development and, pending satisfactory progress, into human clinical trials, is a clear focus for the Company,” CEO Dr Tim Mitchell said in a statement.

“Our strategic goal is to generate compelling evidence for the potential of these candidates in their respective disease areas to facilitate a licensing agreement at an optimal value. In the meantime, we will continue discussions with potential licence partners for these exciting candidates," he added.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Big Picture
February 22 2019

Related Articles

man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use